Allogene Therapeutics
Develops off-the-shelf CAR T candidates for cancer and autoimmune disease.
Something off on this page? Send us feedback.
Profile
Builds healthy-donor CAR T candidates rather than approved products, with clinical work centered on cema-cel, ALLO-329, and ALLO-316. Development depends on trial data, regulatory acceptance, manufacturing readiness, financing, and partner-controlled gene-editing rights.
Develops healthy-donor, off-the-shelf CAR T candidates for cancer and autoimmune disease. Current clinical focus centers on cema-cel for large B-cell lymphoma, ALLO-329 for autoimmune disease, and ALLO-316 for renal-cell carcinoma.
Operations are concentrated in California, while rights and trials span the United States, Europe and other partner territories. The company runs one reportable segment and has no approved commercial product, so collaboration revenue and financing support development work.
Execution depends on clinical data, regulatory acceptance, donor-cell manufacturing, and access to licensed gene-editing technology from partners such as Cellectis, Servier and Arbor. Cema-cel also relies on minimal-residual-disease testing to identify eligible lymphoma patients.
Company facts
Key statistics
Year to date +49.3% · Average volume (30d) 5.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | JP Morgan | Upgrade | Underweight | Neutral | ||
| Apr 14, 2026 | Bernstein | Reiterate | Market Perform | $3.85 | ||
| Apr 14, 2026 | Robert W. Baird | Target | $11 | $9 | ||
| Jan 9, 2026 | Citizens | Upgrade | Market Perform | Market Outperform | ||
| Oct 10, 2025 | JP Morgan | Downgrade | Neutral | Underweight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.17 | −$0.13 | +24.1% | $2.5K | $4.6M | +185,500.0% | −4.35% |
| May 13, 2026Q1 FY26 | −$0.19 | −$0.18 | +5.3% | $2.2K | — | — | −8.15% |
| Mar 12, 2026Q4 FY25 | −$0.25 | −$0.17 | +32.0% | $2.5K | — | — | −2.83% |
| Nov 6, 2025Q3 FY25 | −$0.23 | −$0.19 | +17.4% | $1.8K | — | — | +12.38% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $4.6M | |
| Gross profit | −$3.1M | −$40.2M | −$31.2M | −$3.1M | −$2.9M | $4.6M | |
| Operating income | −$65.2M | −$56.8M | −$44.9M | −$42.4M | −$46.1M | −$46.9M | |
| Net income | −$59.7M | −$50.9M | −$41.4M | −$38.8M | −$42.6M | −$42.7M | |
| Diluted EPS | −$0.28 | −$0.23 | −$0.19 | −$0.17 | −$0.18 | −$0.13 | |
| Gross margin | — | — | — | — | — | 100.0% | |
| Operating margin | — | — | — | — | — | -1,011.2% |
Fiscal years (4-quarter sums)FY21 $38.5M · FY22 $243.0K · FY23 $30.0K · FY24 $22.0K · FY25 $0
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $332.6M · Total debt $70.4M · Total assets $550.1M · Shareholders' equity $436.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 345.16M · Float 260.25M · 75.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 30.15M | 8.73% | 13F | Aug 7, 2026 |
| Frazier Life Sciences Management, L.P. | 22.45M | 6.50% | 13F | Aug 14, 2026 |
| Pfizer Inc | 22.03M | 6.38% | 13F | Aug 13, 2026 |
| State Street Corp | 19.03M | 5.51% | 13F | Aug 7, 2026 |
| TPG GP A, LLC | 18.72M | 5.42% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Earl Martin Douglas | officer: SVP, General Counsel | −29,697 | $2.12 |
| Apr 21, 2026 | Annie Yoshiyama | officer: SVP, Finance | −9,586 | $2.31 |
| Mar 31, 2026 | Benjamin Machinas Beneski | officer: SVP, Chief Technical Officer | −2,867 | $2.50 |
| Mar 16, 2026 | David D. Chang | director, officer: President and CEO | −47,763 | $2.47 |
| Mar 16, 2026 | Benjamin Machinas Beneski | officer: SVP, Chief Technical Officer | −4,835 | $2.47 |
Peers
- Gilead Sciences
Approved CD19 CAR T incumbent in LBCL through Kite
- Bristol-Myers Squibb
Approved CD19 CAR T and RCC immunotherapy overlap
- CRISPR Therapeutics
Gene-edited allogeneic CAR T across CD19, CD70, and autoimmune
- Cabaletta Bio
Late-stage CD19 CAR T autoimmune peer in rheumatology
- Caribou Biosciences
Clinical allogeneic anti-CD19 CAR T peer in LBCL
- Kyverna Therapeutics
Autoimmune CD19 CAR T peer with autologous and allogeneic formats
- Novartis (ADR)
CD19 CAR T incumbent through Kymriah
- Cellectis (ADR)
TALEN allogeneic CAR T platform peer and cema-cel originator
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Cabaletta Bio | $3.18 | +2.25% | $508.7M | — | — | — | — |
| Caribou Biosciences | $1.65 | +2.17% | $160.7M | — | — | 16.0 | −43.8% |
| Kyverna Therapeutics | $8.53 | +2.03% | $508.9M | — | — | — | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Cellectis (ADR) | $3.41 | −0.58% | $341.4M | — | — | 4.5 | −59.2% |
| Median | 18.9 | 16.0 | 5.6 | +3.3% |